Literature DB >> 20412700

Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation.

Jorge Antonio Esquivel-Valerio1, Luis Felipe Flores-Suárez, Jacqueline Rodríguez-Amado, Mario Alberto Garza-Elizondo, Adrián Rendón, Mario Cesar Salinas-Carmona.   

Abstract

OBJECTIVES: To determine the prevalence of antineutrophil cytoplasm autoantibodies (ANCA) and its antigenic specificities in sera of patients with pulmonary tuberculosis (Tb) before and after treatment. PATIENTS AND METHODS: Sixty-eight patients with culture-proven Tb were studied for the presence of ANCA, both by indirect immunofluorescence (IIF) and ELISA against proteinase-3 (PR3), myeloperoxidase (MPO) and bactericidal/permeability increasing protein (BPI). They were sought before treatment and in 52 of them also after therapy for the infection. High sensitivity C-reactive protein (CRP) was also measured at both times.
RESULTS: ANCA by IIF were found in 3/68 (4.4%) sera prior to treatment, one C-ANCA and two P-ANCA, all recognizing BPI. After treatment, this increased to 15/52 (28.8%), 3 C-ANCA and 12 P-ANCA, the majority directed against BPI (11/15, 73%). BPI-ANCA were positive in 6/68 (8.8%) and 15/52 (28.8%) before and after Tb after treatment initiation (p=0.003). PR3-ANCA and MPO-ANCA were negative in all Tb sera. A positive ANCA test correlated with CRP as inflammatory marker (p=0.001).
CONCLUSIONS: The prevalence of ANCA in culture positive Tb patients is modified by Tb chemotherapy. BPI is the main target antigen for ANCA in tuberculosis and BPI-ANCA increase after treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412700

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  IgM ANCA in healthy individuals and in patients with ANCA-associated vasculitis.

Authors:  L S Jeffs; C A Peh; A Nelson; P G Tan; E Davey; K Chappell; G B Perkins; P R Hurtado
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

2.  Anti-PR3 and anti-MPO antibodies are not present in sera of patients with pulmonary tuberculosis.

Authors:  I Lima; R C Oliveira; M S Cabral; A Atta; S Marchi; E Reis; M G Reis; L Barbosa; M B Santiago
Journal:  Rheumatol Int       Date:  2014-04-10       Impact factor: 2.631

Review 3.  Immunological biomarkers of tuberculosis.

Authors:  Gerhard Walzl; Katharina Ronacher; Willem Hanekom; Thomas J Scriba; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2011-04-08       Impact factor: 53.106

Review 4.  Tuberculosis and Autoimmunity.

Authors:  Irina V Belyaeva; Anna N Kosova; Andrei G Vasiliev
Journal:  Pathophysiology       Date:  2022-06-13

5.  The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis.

Authors:  Ori Elkayam; Daniele Bendayan; Refael Segal; Yinon Shapira; Boris Gilburd; Sandra Reuter; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Rheumatol Int       Date:  2012-08-04       Impact factor: 3.580

6.  A case report of granulomatous polyangiitis complicated by tuberculous lymphadenitis.

Authors:  Yuki Iijima; Yoichi Kobayashi; Yoshinori Uchida; Toshiharu Tsutsui; Yumiko Kakizaki; Tsukasa Naganuma; Katsuhiko Tsukamoto; Toshio Oyama; Yoshihiro Miyashita
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 7.  Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases.

Authors:  Kallirroi S Kyriakidi; Vasileios E Tsianos; Evaggelos Karvounis; Dimitrios K Christodoulou; Konstantinos H Katsanos; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2016-03-24

8.  Pulmonary granulomas in a patient with positive ANCA and history of tuberculosis: case report.

Authors:  B Wong; E Tan; A McLean-Tooke
Journal:  BMC Pulm Med       Date:  2020-08-14       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.